Press Releases Press Releases Year None20202019201820172016 Date Title August 4, 2020 UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital SAN FRANCISCO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercules July 31, 2020 UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates SOUTH SAN FRANCISCO, Calif. , July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June July 29, 2020 UPDATE – UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results SAN FRANCISCO , July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended July 24, 2020 UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results SAN FRANCISCO , July 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended July 6, 2020 UNITY Biotechnology Announces CFO Transition Lynne Sullivan appointed interim chief financial officer SAN FRANCISCO , July 06, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that July 1, 2020 UNITY Biotechnology, Inc. Provides Updates on Lead Development Programs – Topline 12-week results for Phase 2 study of UBX0101 in osteoarthritis expected in 3Q 2020 – – First-in-human study for UBX1325 in age-related eye disease expected to commence in 2H 2020 – SOUTH SAN FRANCISCO, Calif. , July 01, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. June 11, 2020 UNITY Biotechnology to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference SAN FRANCISCO , June 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the May 7, 2020 UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the first quarter ended March May 4, 2020 UNITY Biotechnology, Inc. to Announce First Quarter 2020 Financial Results SAN FRANCISCO , May 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the first quarter ended March 31, 2020 UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101 – Topline 12- and 24-week results expected in 2H 2020 – SAN FRANCISCO , March 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
